About this data
What it is
An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
Who files it
The investor, within days of crossing 5%, and again whenever the stake changes materially.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.

All of this comes from public filings.

Filings per day, last 30 days

0200400600800Oct 17 · 13D (activist): 0Oct 17 · 13G (passive): 0Oct 17Oct 18 · 13D (activist): 0Oct 18 · 13G (passive): 0Oct 19 · 13D (activist): 13Oct 19 · 13G (passive): 75Oct 20 · 13D (activist): 16Oct 20 · 13G (passive): 34Oct 21 · 13D (activist): 11Oct 21 · 13G (passive): 31Oct 21Oct 22 · 13D (activist): 16Oct 22 · 13G (passive): 48Oct 23 · 13D (activist): 13Oct 23 · 13G (passive): 24Oct 24 · 13D (activist): 0Oct 24 · 13G (passive): 0Oct 25 · 13D (activist): 0Oct 25 · 13G (passive): 0Oct 25Oct 26 · 13D (activist): 19Oct 26 · 13G (passive): 25Oct 27 · 13D (activist): 16Oct 27 · 13G (passive): 380Oct 28 · 13D (activist): 22Oct 28 · 13G (passive): 60Oct 29 · 13D (activist): 16Oct 29 · 13G (passive): 47Oct 29Oct 30 · 13D (activist): 16Oct 30 · 13G (passive): 343Oct 31 · 13D (activist): 0Oct 31 · 13G (passive): 0Nov 1 · 13D (activist): 0Nov 1 · 13G (passive): 0Nov 2 · 13D (activist): 20Nov 2 · 13G (passive): 36Nov 2Nov 3 · 13D (activist): 22Nov 3 · 13G (passive): 45Nov 4 · 13D (activist): 19Nov 4 · 13G (passive): 67Nov 5 · 13D (activist): 15Nov 5 · 13G (passive): 311Nov 6 · 13D (activist): 40Nov 6 · 13G (passive): 191Nov 6Nov 7 · 13D (activist): 0Nov 7 · 13G (passive): 0Nov 8 · 13D (activist): 0Nov 8 · 13G (passive): 0Nov 9 · 13D (activist): 40Nov 9 · 13G (passive): 140Nov 10 · 13D (activist): 27Nov 10 · 13G (passive): 289Nov 10Nov 11 · 13D (activist): 0Nov 11 · 13G (passive): 0Nov 12 · 13D (activist): 34Nov 12 · 13G (passive): 277Nov 13 · 13D (activist): 26Nov 13 · 13G (passive): 690Nov 14 · 13D (activist): 0Nov 14 · 13G (passive): 0Nov 14Nov 15 · 13D (activist): 0Nov 15 · 13G (passive): 0
0200400600800Oct 17 · 13D (activist): 0Oct 17 · 13G (passive): 0Oct 17Oct 18 · 13D (activist): 0Oct 18 · 13G (passive): 0Oct 19 · 13D (activist): 13Oct 19 · 13G (passive): 75Oct 20 · 13D (activist): 16Oct 20 · 13G (passive): 34Oct 21 · 13D (activist): 11Oct 21 · 13G (passive): 31Oct 21Oct 22 · 13D (activist): 16Oct 22 · 13G (passive): 48Oct 23 · 13D (activist): 13Oct 23 · 13G (passive): 24Oct 24 · 13D (activist): 0Oct 24 · 13G (passive): 0Oct 25 · 13D (activist): 0Oct 25 · 13G (passive): 0Oct 25Oct 26 · 13D (activist): 19Oct 26 · 13G (passive): 25Oct 27 · 13D (activist): 16Oct 27 · 13G (passive): 380Oct 28 · 13D (activist): 22Oct 28 · 13G (passive): 60Oct 29 · 13D (activist): 16Oct 29 · 13G (passive): 47Oct 29Oct 30 · 13D (activist): 16Oct 30 · 13G (passive): 343Oct 31 · 13D (activist): 0Oct 31 · 13G (passive): 0Nov 1 · 13D (activist): 0Nov 1 · 13G (passive): 0Nov 2 · 13D (activist): 20Nov 2 · 13G (passive): 36Nov 2Nov 3 · 13D (activist): 22Nov 3 · 13G (passive): 45Nov 4 · 13D (activist): 19Nov 4 · 13G (passive): 67Nov 5 · 13D (activist): 15Nov 5 · 13G (passive): 311Nov 6 · 13D (activist): 40Nov 6 · 13G (passive): 191Nov 6Nov 7 · 13D (activist): 0Nov 7 · 13G (passive): 0Nov 8 · 13D (activist): 0Nov 8 · 13G (passive): 0Nov 9 · 13D (activist): 40Nov 9 · 13G (passive): 140Nov 10 · 13D (activist): 27Nov 10 · 13G (passive): 289Nov 10Nov 11 · 13D (activist): 0Nov 11 · 13G (passive): 0Nov 12 · 13D (activist): 34Nov 12 · 13G (passive): 277Nov 13 · 13D (activist): 26Nov 13 · 13G (passive): 690Nov 14 · 13D (activist): 0Nov 14 · 13G (passive): 0Nov 14Nov 15 · 13D (activist): 0Nov 15 · 13G (passive): 0

13D (activist) 13G (passive)

Latest ownership filings

Reset

Showing: ticker NAMS

Latest ownership filings
FiledScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders.CompanyInvestorShares% of sharesFiling
Nov 5, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Abigail P. Johnson11.94M10.0%SCHEDULE 13G/A ↗
Nov 5, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
FMR LLC11.94M10.0%SCHEDULE 13G/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Patrick J. Heron7.33M6.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
James N. Topper7.33M6.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls Xii, L.L.C.365,2310.3%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls Xii, L.P.365,2310.3%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Frazier Life Sciences XII, L.P.365,2310.3%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls Xi, L.L.C.1.32M1.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls Xi, L.P.1.32M1.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Frazier Life Sciences XI, L.P.1.32M1.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmlsp, L.L.C.10.42M8.7%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmlsp, L.P.10.42M8.7%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Frazier Life Sciences Public Fund, L.P.10.42M8.7%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls X, L.L.C.7.33M6.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Fhmls X, L.P.7.33M6.1%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Frazier Lifesciences Sponsor LLC3.97M3.3%SCHEDULE 13D/A ↗
Sep 22, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Frazier Life Sciences X, L.P.7.33M6.1%SCHEDULE 13D/A ↗
Aug 6, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Abigail P. Johnson10.34M8.8%SCHEDULE 13G/A ↗
Aug 6, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
FMR LLC10.34M8.8%SCHEDULE 13G/A ↗
Jun 4, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Capital World Investors12.19M10.4%SCHEDULE 13G/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCIP Life Sciences Associates, LP10,8570.0%SCHEDULE 13D/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS II Equity Opportunities, LP375,5120.3%SCHEDULE 13D/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS II Investco, LP114,0170.1%SCHEDULE 13D/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Bain Capital Life Sciences Fund II, L.P.89,1420.1%SCHEDULE 13D/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Bain Capital Life Sciences Opportunities III, LP1.26M1.1%SCHEDULE 13D/A ↗
May 14, 2026SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS Fund III Investments, LP2.06M1.8%SCHEDULE 13D/A ↗
May 6, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Abigail P. Johnson8.77M7.6%SCHEDULE 13G/A ↗
May 6, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
FMR LLC8.77M7.6%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Rose Sharon Shabet4.20M3.7%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
David C. Ott4.20M3.7%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Halvorsen Ole Andreas4.20M3.7%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Drawdown (Aggregator) LP1.39M1.2%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Drawdown Portfolio GP LLC1.39M1.2%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Drawdown GP LLC1.39M1.2%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Illiquid Investments Sub-Master LP2.82M2.5%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Portfolio GP LLC2.82M2.5%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities GP LLC2.82M2.5%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Opportunities Parent GP LLC4.20M3.7%SCHEDULE 13G/A ↗
Feb 17, 2026SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Viking Global Investors LP4.20M3.7%SCHEDULE 13G/A ↗
Feb 5, 2026SCHEDULE 13GNAMS
NewAmsterdam Pharma Company N.V.
Abigail P. Johnson6.41M5.7%SCHEDULE 13G ↗
Feb 5, 2026SCHEDULE 13GNAMS
NewAmsterdam Pharma Company N.V.
FMR LLC6.41M5.7%SCHEDULE 13G ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCIP Life Sciences Associates, LP10,8570.0%SCHEDULE 13D/A ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS II Equity Opportunities, LP375,5120.3%SCHEDULE 13D/A ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS II Investco, LP297,5570.3%SCHEDULE 13D/A ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Bain Capital Life Sciences Fund II, L.P.89,1420.1%SCHEDULE 13D/A ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Bain Capital Life Sciences Opportunities III, LP1.26M1.1%SCHEDULE 13D/A ↗
Dec 4, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS Fund III Investments, LP5.38M4.7%SCHEDULE 13D/A ↗
Nov 13, 2025SCHEDULE 13G/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
Capital World Investors9.82M8.7%SCHEDULE 13G/A ↗
Nov 7, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCIP Life Sciences Associates, LP11.42M10.0%SCHEDULE 13D/A ↗
Nov 7, 2025SCHEDULE 13D/A (amended)NAMS
NewAmsterdam Pharma Company N.V.
BCLS II Equity Opportunities, LP11.42M10.0%SCHEDULE 13D/A ↗

The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:09 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances